NORTHBROOK, Ill., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that three outcomes studies demonstrating the clinical and economic impact of the Verigene® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held in Washington, DC on September 5 – 9, 2014.
Each of the three studies paired Verigene BC-GP for rapid sepsis diagnostic testing with active antimicrobial stewardship programs to assess the impact on antimicrobial optimization and patient outcomes. Settings included two large teaching institutions and a non-teaching community hospital.
The following posters will be presented on Sunday, September 7th from 11:00 a.m. to 1:00 p.m. in Exhibit Hall B:
- D-908: "Utilization of a DNA Hybridization-Based, Rapid Molecular Diagnostic Test for Faster Bacterial Identification and Antimicrobial Optimization in Bacteremic Patients," T.E. Bias, Hahnemann University Hospital and Drexel University College of Medicine (Philadelphia, PA).
- D-912: "Impact of Integrating the Nanosphere Verigene Gram-Positive Blood Culture (BC-GP) Test with Antimicrobial Stewardship in a Non-Teaching Community Hospital," B. Crane, Blount Memorial Hospital (Maryville, TN).
- D-915: "Outcomes Utilizing Pharmacist Intervention and Rapid Molecular Diagnostic Technology (RMDT) in Patients with Gram-Positive Bloodstream Infections (BSI)," S.L. Revolinski, Froedtert Hospital (Milwaukee, WI).
Posters D-908 and D-912 will also be featured in a guided tour of the Poster Hall on Saturday, September 6th from 1:00 to 2:00 p.m., in which the most intriguing posters and latest discoveries on the "Clinical Impact of Novel Diagnostics for the Detection of Bacteremia" will be discussed.
Nanosphere representatives will be exhibiting at Booth #315 in the ICAAC Exhibit Hall.
About the Verigene® System
The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the bloodstream, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.
About Nanosphere, Inc.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
CONTACT: Investors: Roger Moody Chief Financial Officer Nanosphere, Inc. 847-400-9021 email@example.com Michael Rice Founding Partner LifeSci Advisors 646-597-6979 firstname.lastname@example.org Media: Lindsey Saxon Director of Communications Nanosphere, Inc. 847-400-9173 email@example.com